Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.45 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.45 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100494 | 1.00 | NR1H4 (0.51) | NR1H4RAB9ANPC1KCNMA1P2RX1 | |
| SCHEMBL23675432 | 0.89 | RAB9A (0.55) | NR1H4RAB9ANPC1KCNMA1P2RX1 | |
| SCHEMBL26095655 | 0.88 | RAB9A (0.54) | NR1H4RAB9ANPC1KCNMA1P2RX1 | |
| SCHEMBL26097532 | 0.87 | GRM4 (0.50) | RAB9ANPC1KCNMA1S1PR1F10 | |
| SCHEMBL30100492 | 0.85 | NPC1 (0.54) | NR1H4RAB9ANPC1KCNMA1S1PR1 | |
| SCHEMBL23675395 | 0.85 | NPC1 (0.54) | NR1H4RAB9ANPC1KCNMA1S1PR1 | |
| SCHEMBL23675431 | 0.80 | P2RX1 (0.58) | NR1H4RAB9ANPC1KCNMA1P2RX1 | |
| Hydrochloric Acid SCHEMBL23675414 | 0.78 | MEN1 (0.51) | RAB9ANPC1KCNMA1P2RX1TMPRSS4 | |
| SCHEMBL26095759 | 0.78 | KCNMA1 (0.55) | RAB9ANPC1KCNMA1KMT2AGAA | |
| SCHEMBL23675406 | 0.78 | TAS1R3 (0.63) | RAB9ANPC1KCNMA1P2RX1TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021151104-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | EIF2AK2, SARS1, ACE | NR1H4 4072/4885RAB9A 4307/4885NPC1 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.